CoChat

Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

The inflamed liver in chronic hepatitis B virus (HBV) infection (CHB) is characterized by a large influx of non–virus-specific CD8 T cells. Little is known about the functional capacity of these lymphocytes, which could provide insights into mechanisms of failure of viral control and liver damage in this setting. We compared the effector function of total circulating and intrahepatic CD8 T cells in CHB patients and healthy donors. We demonstrated that CD8 T cells from CHB patients, regardless of their antigen specificity, were impaired in their ability to produce interleukin-2 and proliferate upon TCR-dependent stimulation. In contrast, these CD8 T cells had preserved production of the proinflammatory cytokines interferon-γ and tumor necrosis factor-α. This aberrant functional profile was partially attributable to down-regulation of the proximal T cell receptor signaling molecule CD3ζ, and could be corrected in vitro by transfection of CD3ζ or replenishment of the amino acid arginine required for its expression. We provide evidence for depletion of arginine in the inflamed hepatic microenvironment as a potential mechanism for these defects in global CD8 T cell signaling and function. These data imply that polarized CD8 T cells within the HBV-infected liver may impede proliferative antiviral effector function, while contributing to the proinflammatory cytokine environment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20072076

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Selective impairment in IL-2 production and proliferation, but elevated IFN-γ, TNF-α, and cytolysis, in CD8 T cells from patients with high viral load. PBMCs were stimulated with mitogens OKT3 (anti-CD3; 1 μg/ml) and anti-CD28 mAb (5 μg/ml), and cytokine production in CD8 T cells was determined by intracellular cytokine staining. (a) Representative dot plots show IL-2, IFN-γ, TNF-α, CD107, and CFSE staining by CD8 T cells in a healthy donor, patient with low viral load (<106 IU/ml HBVDNA), and a patient with high viral load (>106 IU/ml HBVDNA). (bottom) Percentage of CFSE low CD8 T cells in a control (dark gray histogram), low-level carrier (solid black line), and high-level carrier (light gray histogram). The y axis shows the percentage of maximum counts to standardize overlaid histogram heights. (b) Subjects were categorized into groups determined by their viral load/HBeAg status or level of liver inflammation (ALT as a surrogate marker of liver inflammation) and mean (± SEM) production of cytokines IL-2, IFN-γ, TNF-α, the cytolytic marker CD107, and divisions as determined by CFSE are shown for each group after anti-CD3/anti-CD28 stimulation. Background production of cytokines was determined in the unstimulated control, and subtracted from the final readings (*, P < 0.05; **, P < 0.01; ***, P < 0.001, all significance testing by the Mann-Whitney test). (c) Levels of intracellular IL-2 and IFN-γ in the different donors after TCR-independent stimulation with PMA/ionomycin.
Figure 1. Selective impairment in IL-2 production and proliferation, but elevated IFN-γ, TNF-α, and cytolysis, in CD8 T cells from patients with high viral load. PBMCs were stimulated with mitogens OKT3 (anti-CD3; 1 μg/ml) and anti-CD28 mAb (5 μg/ml), and cytokine production in CD8 T cells was determined by intracellular cytokine staining. (a) Representative dot plots show IL-2, IFN-γ, TNF-α, CD107, and CFSE staining by CD8 T cells in a healthy donor, patient with low viral load (<106 IU/ml HBVDNA), and a patient with high viral load (>106 IU/ml HBVDNA). (bottom) Percentage of CFSE low CD8 T cells in a control (dark gray histogram), low-level carrier (solid black line), and high-level carrier (light gray histogram). The y axis shows the percentage of maximum counts to standardize overlaid histogram heights. (b) Subjects were categorized into groups determined by their viral load/HBeAg status or level of liver inflammation (ALT as a surrogate marker of liver inflammation) and mean (± SEM) production of cytokines IL-2, IFN-γ, TNF-α, the cytolytic marker CD107, and divisions as determined by CFSE are shown for each group after anti-CD3/anti-CD28 stimulation. Background production of cytokines was determined in the unstimulated control, and subtracted from the final readings (*, P < 0.05; **, P < 0.01; ***, P < 0.001, all significance testing by the Mann-Whitney test). (c) Levels of intracellular IL-2 and IFN-γ in the different donors after TCR-independent stimulation with PMA/ionomycin.CC BY-NC-SA · PubMed Central
Figure 2. Determination of IL-2 and IFN-γ production by CD8 T cells after stimulation with HLA-A2–restricted viral peptides. (a) Representative flow cytometric dot plots to show distribution of IFN-γ and IL-2–positive responder cells after ex vivo stimulation with peptides (for IFN-A, CMV, HBV envelope pool) in a healthy donor and in a high-level carrier. All ex vivo responses were in the range of 0.1–4% after subtraction of background readings. A response was determined as any reading > mean + 2SD of background. (b) Cumulative data to show mean IFN-γ/IL-2 ratio after stimulation with peptides (NLV, •; EBV, ⋄; FLU, □; HBV c18-27/ env pool, ⊙) for controls, and patients with low (<106 IU/ml) and high (>106 IU/ml) viral load. (c) Histogram to show proportion of double-positive (IFN-γ+IL-2+/IFN-γ+) CD8 T cells in controls and patients after stimulation with the NLV peptide of CMV ex vivo. Mean and SEM are shown.
Figure 2. Determination of IL-2 and IFN-γ production by CD8 T cells after stimulation with HLA-A2–restricted viral peptides. (a) Representative flow cytometric dot plots to show distribution of IFN-γ and IL-2–positive responder cells after ex vivo stimulation with peptides (for IFN-A, CMV, HBV envelope pool) in a healthy donor and in a high-level carrier. All ex vivo responses were in the range of 0.1–4% after subtraction of background readings. A response was determined as any reading > mean + 2SD of background. (b) Cumulative data to show mean IFN-γ/IL-2 ratio after stimulation with peptides (NLV, •; EBV, ⋄; FLU, □; HBV c18-27/ env pool, ⊙) for controls, and patients with low (<106 IU/ml) and high (>106 IU/ml) viral load. (c) Histogram to show proportion of double-positive (IFN-γ+IL-2+/IFN-γ+) CD8 T cells in controls and patients after stimulation with the NLV peptide of CMV ex vivo. Mean and SEM are shown.CC BY-NC-SA · PubMed Central
Figure 3. Intrahepatic CD8 T cells from patients with CHB are biased toward IFN-γ over IL-2 production. (a) Intrahepatic CD8 T cells were isolated from liver biopsies, and cytokine production was determined by intracellular staining after anti-CD3/anti-CD28 stimulation. Representative dot plots show IL-2 and IFN-γ production by CD8 T cells for a typical patient with chronic HBV and a patient with nonviral liver pathology. (b) After mitogenic stimulation, the ratio of IFN-γ/IL-2 production by intrahepatic CD8 T cells was determined for six patients with CHB and six patients without CHB. Ratios are plotted in the histogram shown.
Figure 3. Intrahepatic CD8 T cells from patients with CHB are biased toward IFN-γ over IL-2 production. (a) Intrahepatic CD8 T cells were isolated from liver biopsies, and cytokine production was determined by intracellular staining after anti-CD3/anti-CD28 stimulation. Representative dot plots show IL-2 and IFN-γ production by CD8 T cells for a typical patient with chronic HBV and a patient with nonviral liver pathology. (b) After mitogenic stimulation, the ratio of IFN-γ/IL-2 production by intrahepatic CD8 T cells was determined for six patients with CHB and six patients without CHB. Ratios are plotted in the histogram shown.CC BY-NC-SA · PubMed Central
Figure 4. CD3ζ is down-regulated in both peripheral and intrahepatic CD8 from patients with chronic HBV. PBMCs or intrahepatic lymphocytes isolated from biopsy tissue were surface stained for CD3ε and CD8, fixed, permeabilized, and stained for intracellular CD3ζ or its isotype. A tight lymphocyte gate and secondary gate over CD3ε+CD8 cells has been applied. A marker was applied at the edge of the isotype control (solid black line) and the proportion of CD8 to the right of this line represented the CD3ζ+ fraction. (a) Representative flow cytometric histogram illustrating CD3ζ expression (as a percentage and as mean fluorescence intensity [MFI]) for a chronic HBV-infected patient with high viral load (>106 IU/ml; dashed line) and a healthy control (gray). (b) CD3ζ levels, shown as both MFI and percentage of CD3ζ+ in the total CD8 are shown against viral load (top), and percentage values are further broken down by HBeAg status and ALT (bottom). (c) Histogram to illustrate differential expression of CD3ζ by peripheral (dark gray) and intrahepatic (light gray) CD8 from a CHB donor (dotted line, isotype). (d) The difference in CD3ζ expression between intrahepatic and peripheral CD8 is plotted for each patient with HBV/non-HBV–related liver disease.
Figure 4. CD3ζ is down-regulated in both peripheral and intrahepatic CD8 from patients with chronic HBV. PBMCs or intrahepatic lymphocytes isolated from biopsy tissue were surface stained for CD3ε and CD8, fixed, permeabilized, and stained for intracellular CD3ζ or its isotype. A tight lymphocyte gate and secondary gate over CD3ε+CD8 cells has been applied. A marker was applied at the edge of the isotype control (solid black line) and the proportion of CD8 to the right of this line represented the CD3ζ+ fraction. (a) Representative flow cytometric histogram illustrating CD3ζ expression (as a percentage and as mean fluorescence intensity [MFI]) for a chronic HBV-infected patient with high viral load (>106 IU/ml; dashed line) and a healthy control (gray). (b) CD3ζ levels, shown as both MFI and percentage of CD3ζ+ in the total CD8 are shown against viral load (top), and percentage values are further broken down by HBeAg status and ALT (bottom). (c) Histogram to illustrate differential expression of CD3ζ by peripheral (dark gray) and intrahepatic (light gray) CD8 from a CHB donor (dotted line, isotype). (d) The difference in CD3ζ expression between intrahepatic and peripheral CD8 is plotted for each patient with HBV/non-HBV–related liver disease.CC BY-NC-SA · PubMed Central
Figure 5. CD28 is down-regulated in CD8 T cells from patients with high viral load. (a) Representative dot plot to show the coexpression of CD28 and CD3ζ in CD8 T cells in a patient with high viral load. (b) Flow cytometric histogram to show the proportion of CD8 T cells that are CD28+ in a patient with high viral load (gray) and a healthy donor (dashed line). (c) Cumulative data for CD28 expression is shown against viral load, HBeAg status, and ALT level.
Figure 5. CD28 is down-regulated in CD8 T cells from patients with high viral load. (a) Representative dot plot to show the coexpression of CD28 and CD3ζ in CD8 T cells in a patient with high viral load. (b) Flow cytometric histogram to show the proportion of CD8 T cells that are CD28+ in a patient with high viral load (gray) and a healthy donor (dashed line). (c) Cumulative data for CD28 expression is shown against viral load, HBeAg status, and ALT level.CC BY-NC-SA · PubMed Central
Figure 6. Reconstitution of CD3ζ and CD28 levels with a chimeric receptor reverses the IL-2 defect. (a) Histogram shows transfection efficiency in a representative patient after transfection of a chimeric receptor with an extracellular CD33-binding domain and intracellular CD3ζ and CD28 domains. (b) After antigen-specific stimulation through the chimeric receptor, TCR (anti-CD3/anti-CD28), or both together, IL-2 production was determined by ELISA. Mean and SEM of IL-2 production is shown for three individuals after the varying stimuli.
Figure 6. Reconstitution of CD3ζ and CD28 levels with a chimeric receptor reverses the IL-2 defect. (a) Histogram shows transfection efficiency in a representative patient after transfection of a chimeric receptor with an extracellular CD33-binding domain and intracellular CD3ζ and CD28 domains. (b) After antigen-specific stimulation through the chimeric receptor, TCR (anti-CD3/anti-CD28), or both together, IL-2 production was determined by ELISA. Mean and SEM of IL-2 production is shown for three individuals after the varying stimuli.CC BY-NC-SA · PubMed Central
Figure 7. Replenishment of arginine restores CD8 expression of CD3ζ, accompanied by a recovery in IL-2 production and proliferation. (a) Histogram illustrates effect of overnight culture in medium on CD3ζ levels (black histogram) compared with when measured directly ex vivo (gray histogram). Isotype control is shown as the dotted line. IL-2 production was determined in parallel before and after culture and representative plots are shown. (b) Cumulative data to show change in CD28 (P = nonsignificant) and CD3ζ expression (P < 0.0001) after in vitro culture, compared with ex vivo culture, in five and nine patients, respectively. (c) CD3ζ expression in CD8 T cells was determined directly ex vivo, and then again after overnight culture in medium with or without l-arginine (0.2 g/liter). (d) To investigate whether the presence of l-arginine affects CD8 T cell proliferation, PBMCs were preincubated with medium with or without l-arginine for 24 h, stained with CFSE, and resuspended in their respective mediums in the presence of a CD3ζ-dependent stimulus for 6 d. A gate has been applied on CD8 T cells. (e) To determine the effect of l-arginine on proliferation of HBV-specific CD8+ T cells, PBMCs from HLA-A2+ patients who had resolved HBV infection were stimulated with core 18–27 peptide for 7 d and detected with an HLA-A2/c18-27–specific tetramer. Representative dot plots depict the HBV-specific CD8+ population expanded at 1 wk, along with the number of divisions these populations have undergone, determined by CFSE dilution, in the presence (top) or absence (bottom) of l-arginine. (f) Cumulative data illustrate the effect of depleting l-arginine on the percentage of tetramer-positive populations dividing by 1 wk in 5 patients (P < 0.01). (g) HLA-A2/core18-27 tetramer-positive CD8 were compared after 7-d peptide stimulation of PBMCs incubated in a range of l-arginine concentrations (0 μM, 5 μM, 25 μM, 50 μM, 150 μM, and 1 mM).
Figure 7. Replenishment of arginine restores CD8 expression of CD3ζ, accompanied by a recovery in IL-2 production and proliferation. (a) Histogram illustrates effect of overnight culture in medium on CD3ζ levels (black histogram) compared with when measured directly ex vivo (gray histogram). Isotype control is shown as the dotted line. IL-2 production was determined in parallel before and after culture and representative plots are shown. (b) Cumulative data to show change in CD28 (P = nonsignificant) and CD3ζ expression (P < 0.0001) after in vitro culture, compared with ex vivo culture, in five and nine patients, respectively. (c) CD3ζ expression in CD8 T cells was determined directly ex vivo, and then again after overnight culture in medium with or without l-arginine (0.2 g/liter). (d) To investigate whether the presence of l-arginine affects CD8 T cell proliferation, PBMCs were preincubated with medium with or without l-arginine for 24 h, stained with CFSE, and resuspended in their respective mediums in the presence of a CD3ζ-dependent stimulus for 6 d. A gate has been applied on CD8 T cells. (e) To determine the effect of l-arginine on proliferation of HBV-specific CD8+ T cells, PBMCs from HLA-A2+ patients who had resolved HBV infection were stimulated with core 18–27 peptide for 7 d and detected with an HLA-A2/c18-27–specific tetramer. Representative dot plots depict the HBV-specific CD8+ population expanded at 1 wk, along with the number of divisions these populations have undergone, determined by CFSE dilution, in the presence (top) or absence (bottom) of l-arginine. (f) Cumulative data illustrate the effect of depleting l-arginine on the percentage of tetramer-positive populations dividing by 1 wk in 5 patients (P < 0.01). (g) HLA-A2/core18-27 tetramer-positive CD8 were compared after 7-d peptide stimulation of PBMCs incubated in a range of l-arginine concentrations (0 μM, 5 μM, 25 μM, 50 μM, 150 μM, and 1 mM).CC BY-NC-SA · PubMed Central
Figure 8. Depletion of serum l-arginine is associated with elevated serum and liver arginase activity during periods of HBV disease activity in patients with CHB. (a) Serum l-arginine levels were compared in healthy donors (n = 21), patients with low-to-moderate liver inflammation (ALT < 100 IU/liter; n = 13), and patients with high liver inflammation (ALT > 100 IU/liter; n = 11; control vs. high ALT P < 0.01; low ALT vs. high ALT P < 0.05). (b) Graphs depict longitudinal fluctuations in serum arginase activity (dashed line, IU/liter) in association with viral load (solid gray line, HBV DNA, IU/ml) and ALT (shaded histogram, IU/liter) for two patients with flares of CHB. (c) The arginase activity of liver homogenates is shown for five individuals with CHB and five individuals with nonviral liver pathology.
Figure 8. Depletion of serum l-arginine is associated with elevated serum and liver arginase activity during periods of HBV disease activity in patients with CHB. (a) Serum l-arginine levels were compared in healthy donors (n = 21), patients with low-to-moderate liver inflammation (ALT < 100 IU/liter; n = 13), and patients with high liver inflammation (ALT > 100 IU/liter; n = 11; control vs. high ALT P < 0.01; low ALT vs. high ALT P < 0.05). (b) Graphs depict longitudinal fluctuations in serum arginase activity (dashed line, IU/liter) in association with viral load (solid gray line, HBV DNA, IU/ml) and ALT (shaded histogram, IU/liter) for two patients with flares of CHB. (c) The arginase activity of liver homogenates is shown for five individuals with CHB and five individuals with nonviral liver pathology.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 3

  1. 1993, Cancer Res., 53, 5610
  2. 1991, Transplant. Proc., 23, 1436
  3. 1995, Hepatology., 21, 1585

Cited by

See all 263

Metadata

Authors
Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., Bertoletti, A., Akbar, A. N., & Maini, M. K.
Affiliations
  • 1Division of Infection and Immunity
  • Addenbrooke's Hospital (GB)
  • 2Institute of Hepatology
  • Cell Biotech (South Korea) (KR)
  • Agency for Science, Technology and Research (SG)
  • University College London (GB)
Venue
The Journal of Experimental Medicine
Published
2008-08-11
Volume
205
Issue
9
Pages
2111-2124
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2020211914
Cited by
256
References
60
Citations by year
2026: 1 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 16 · 2016: 11 · 2015: 15 · 2014: 20 · 2013: 19 · 2012: 25
FWCI
13.36
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • University College London
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
chronic hepatitis B, CD8+ T cells, T cell dysfunction, T cell receptor signaling, CD3zeta, arginine deprivation, IL-2 production, T cell proliferation, interferon-gamma, TNF-α, liver inflammation, intrahepatic T cells
MeSH terms
Adult, Aged, Female, Hepatitis B virus, Humans, Interferon-gamma, Interleukin-2, Male, Middle Aged, Models, Biological, Tumor Necrosis Factor-alpha, HLA-A2 Antigen, CD8-Positive T-Lymphocytes, Viral Load, Hepatitis B, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.